Previously, it has been demonstrated that SIRT1-activating drugs have immense potential as anticancer drugs, hence targeting SIRT1 might give a novel therapeutic avenue for treating oral cancer [17]. The gene discussed is SIRT1; the disease is lip and oral cavity carcinoma.